Martin Shkreli, center, exits federal court in New York, on, Dec. 17. Shkreli was arrested on alleged securities fraud related to Retrophin Inc., a biotech firm he founded in 2011. Martin Shkreli, the pharmaceutical CEO arrested on securities fraud charges this week, may have made drug price increases notorious in the U.S. But his strategy of finding an old drug, raising its price, and taking the profit is one that's increasingly common among a new breed of drugmakers.